Chinook Therapeutics

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook.

Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing in the phase 1 clinical trial of CHK-336 in healthy volunteers has been voluntarily paused to allow a thorough investigation of a serious adverse event (SAE) that occurred in a single subject following the first dose in the 125 mg multiple ascending dose (MAD) group. Dosing was halted per trial protocol when the event occurred, followed by a voluntary pausing of the trial by Chinook to enable further investigation. The event has been reported to the U.S. Food and Drug Administration (FDA) through a Suspected Unexpected Severe Adverse Reaction (SUSAR) report.

Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers

SEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.

Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.

Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023

SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 3:20 pm ET, as well as 1x1 meetings.

Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 5th Chronic Kidney Disease Drug Development (CKD) Summit in Boston, MA from March 7 – 9, 2023.

Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit

Chinook (KDNY) delivered earnings and revenue surprises of -13.92% and 28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided corporate updates.

Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Travere's FILSPARI (sparsentan) received accelerated approval for IgAN's disease on Feb 17, 2023. Chinook has a similar phase 3 ERA atrasentan that drove a UPCR benefit of 54.7%, and approval of sparsentan based on UPCR only should be net positive for atrasentan.

Chinook: Travere's Sparsentan Approval Is Net Positive

SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer.

Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

Chinook is a clinical-stage biopharmaceutical firm that is developing precision medicines for kidney diseases, including treatments for rare, chronic, and severe kidney conditions. Its lead program, atrasentan, is a potent antagonist of the endothelin A receptor undergoing a phase 3 trial for IgA nephropathy.

Chinook's Atrasentan: A Promising Solution For IgA Nephropathy?

SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 11:20 am ET, as well as 1x1 meetings.

Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference

2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ALIGN data of Atrasentan).

Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts

Vera Therapeutics

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted. The post Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped appeared first on Investor's Business Daily.

Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped

SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings.

Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates

SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced two posters on the BION-1301 and CHK-336 programs being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida. An oral presentation and additional poster on Chinook's collaboration with Evotec will also be presented at ASN Kidney Week 2022 later this afternoon and tomorrow.

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced two posters and three informational posters being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida.

Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced nine abstracts to be presented at ASN Kidney Week 2022 from November 3 – 6, 2022 in Orlando, Florida. Five abstracts will be presented as posters, one abstract will be delivered as an oral presentation and three abstracts will be presented as informational posters.

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022

Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo.

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Chinook (KDNY) delivered earnings and revenue surprises of 1.61% and 83.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Chinook Therapeutics (KDNY) Reports Q2 Loss, Misses Revenue Estimates

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six months ended June 30, 2022.

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Adicet Bio, Inc.

IVERIC bio Inc

Kura Oncology

 Pliant Therapeutics

Rocket Pharma

Caribou Biosciences

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

7 Cheap Biotech Stocks to Buy Now

Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

News for Chinook Therapeutics Stock (KDNY)